Analytical Data
-
基因名
Vibrio cholerae serotype O1 CTXB 蛋白
- Application
-
别名
Cholera enterotoxin B chain Cholera enterotoxin gamma chain Choleragenoid
-
种属
Vibrio cholerae serotype O1
-
表达系统
E. coli
-
标签
N- His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P01556
-
表达区间
22-124aa
-
分子量
15.6 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MICA (MHC class I polypeptide-related sequence A) is a pivotal molecule involved in the immune system's recognition of stressed or transformed cells. MICA, a member of the MHC superfamily, plays a critical role in activating natural killer (NK) cells and CD8+ T cells by interacting with the NKG2D receptor on these immune effector cells. The study of MICA and its recombinant proteins has gained prominence due to its association with cancer progression, viral infections, and autoimmune diseases. Abnormal expression of MICA can serve as a biomarker for various malignancies, making it an attractive target for therapeutic interventions. Researchers have focused on producing recombinant MICA proteins to better understand its structure-function relationships and the dynamics of its interactions with immune cells. Such studies can elucidate MICA's role in tumor immune evasion and inform the development of MICA-based immunotherapies. Furthermore, recombinant MICA proteins can be utilized in diagnostic assays and therapeutic applications, highlighting the molecule's potential as a novel target in cancer immunotherapy and precision medicine. The investigation into MICA’s functional mechanisms continues to advance our understanding of immune regulation and the complexities of tumor-immune interactions, paving the way for innovative treatment strategies.
